M
MAZE THERAPEUTICS, INC. COMMON STOCK
NASDAQ: MAZE (Maze Therapeutics, Inc.)
Last update: 16 hours ago10.85
0.26 (2.46%)
| Previous Close | 10.59 |
| Open | 11.24 |
| Volume | 300,049 |
| Avg. Volume (3M) | 283,101 |
| Market Cap | 475,187,712 |
| Price / Earnings (TTM) | 135.63 |
| Price / Sales | 2.84 |
| 52 Weeks Range | |
| Earnings Date | 31 Mar 2025 |
| Profit Margin | 31.18% |
| Operating Margin (TTM) | 34.38% |
| Diluted EPS (TTM) | 0.080 |
| Total Debt/Equity (MRQ) | 13.52% |
| Current Ratio (MRQ) | 9.76 |
| Operating Cash Flow (TTM) | 75.95 M |
| Levered Free Cash Flow (TTM) | 52.09 M |
| Return on Assets (TTM) | 23.07% |
| Return on Equity (TTM) | 50.48% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Maze Therapeutics, Inc. | Bearish | - |
AIStockmoo Score
2.3
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 5.0 |
| Technical Oscillators | 2.0 |
| Average | 2.25 |
|
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic, or CVRM, diseases, including obesity. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 11.41% |
| % Held by Institutions | 69.10% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 30.00 (JP Morgan, 176.50%) | Buy |
| Median | 28.00 (158.07%) | |
| Low | 19.00 (Guggenheim, 75.12%) | Buy |
| Average | 25.67 (136.59%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 10.50 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Guggenheim | 02 Apr 2025 | 19.00 (75.12%) | Buy | 10.37 |
| 25 Feb 2025 | 19.00 (75.12%) | Buy | 10.57 | |
| JP Morgan | 25 Feb 2025 | 30.00 (176.50%) | Buy | 10.57 |
| Leerink Partners | 25 Feb 2025 | 28.00 (158.06%) | Buy | 10.57 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 31 Mar 2025 | Announcement | Maze Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Highlights |
| 07 Feb 2025 | Announcement | Maze Therapeutics Doses First Patient in Phase 2 HORIZON Clinical Trial Evaluating MZE829 as a Potential Treatment for APOL1 Kidney Disease |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |